Subacute thyroiditis after receiving the COVID-19 vaccine

Area of Science:

• Endocrinology
• Immunology
• Vaccinology

Background:

• The emergence of coronavirus disease 2019 (COVID-19) has been associated with an increase in autoimmune conditions.
• Several cases of subacute thyroiditis (SAT) have been reported globally, including those linked to COVID-19 vaccination.

Observation:

• This study presents data on five cases of vaccine-associated SAT.
• Patients' ages ranged from 31 to 43 years.
• SAT diagnosis occurred after the first dose in 60% of patients and after the second dose in 40%.

Findings:

• Symptoms of SAT appeared approximately 25.2 days (range: 2-44 days) post-vaccination.
• The study evaluated vaccine type, symptom onset, laboratory findings, treatments, and treatment response in these cases.

Implications:

• Subacute thyroiditis following COVID-19 vaccination is a rare but recognized phenomenon.
• Healthcare practitioners should maintain awareness of post-vaccine SAT to ensure timely diagnosis and appropriate clinical management.
• Early recognition and intervention can potentially improve the clinical course and outcomes for affected individuals.